ZOLL Medical Corporation

While Chief of the Cardiac Clinic at Beth Israel Hospital, Paul M. Zoll, M.D., demonstrates that external electrical stimulation of a patient's chest during cardiac arrest can produce an effective heartbeat.

ベス・イスラエル病院循環器部長(当時)のZoll博士が、体外電気的刺激が、心肺停止患者の拍動の復活に有効であることを実証。

Dr. Zoll is the first physician to successfully use external defibrillation to regulate heart rhythms in patients. This discovery contributes significantly to the decrease in heart disease mortality.

With technical collaborators, Dr. Zoll develops a way to display the heart's cardiac electrical activity on an oscilloscopic screen. This leads to the development of cardiac monitors and other programs found in modern cardiac care units.

Zoll博士が、体外除細動器を最初に臨床使用し、成功を収める。心臓の電気活動をオシロスコープに表示する手法を開発。心電計の基礎を築く。

Dr. Zoll discovers that external electrical countershock is effective in terminating supraventricular tachycardia and ventricular tachycardia. This procedure becomes widely used in the treatment of these arrhythmias and is found to be safer than administering large doses of antiarrhythmic drugs.

Dr. Zoll develops a method for long-term direct electrical heart stimulation through an implanted pacemaker.

Zoll博士が、植込み型ペースメーカーによる長期的直接心臓刺激の手法を開発。

Dr. Zoll receives the Albert Lasker Award for Clinical Medical Research, the most coveted award in medical science.

Dr. Zoll becomes Clinical Professor of Medicine, Emeritus, at Harvard Medical School.

ZOLL® is incorporated by the company's co-founders, including Dr. Zoll, Leigh Stein, and Thomas Claflin. William Bright, Chairman, and Rolf Stutz, CEO, subsequently join ZOLL.

ZOLL Medical Corporation設立

The ZOLL NTP® 1000, a non-invasive temporary pacemaker based on Dr. Zoll's research, is introduced.

非侵襲の短期ペースメーカーZOLL NTP 1000販売開始

ペースメーカー／除細動器／モニター一体型のZOLL PD 1200販売開始

Introduces adult multi-function electrodes, which provide well-tolerated pacing, effective defibrillation, cardioversion, and monitoring.

ZOLL becomes a public company.

Releases the PD 1400 pacemaker/defibrillator/monitor, the smallest device of its kind available for critical patient transport and pre-hospital treatment.

The American Heart Association elevates non-invasive pacing to the initial treatment of choice for certain serious patient conditions. ZOLL is the market leader for this technology.

Receives 510(k) marketing clearance from the FDA for the PD/D 2000 automated external defibrillator (AED)/advisory defibrillator.

AEDがFDA承認

Establishes a subsidiary in the Netherlands.

Launches ZOLL 1600, the first fully upgradeable and configurable AED/manual external defibrillator.

Introduces the first modular AC power supply/battery charger for use in hospitals on the ZOLL 1400, 1600, and 2000 family of defibrillators.

Acquires Westech Mobile Solutions, adding software-based information products to the pre-hospital product line.

Makes an equity investment in LIFECOR, Inc., a medical equipment company that makes LifeVest®, the first and only wearable defibrillator.

Introduces the ZOLL 1700, the first fully integrated AED/manual external defibrillator for basic life support (BLS) and advanced cardiac life support (ACLS) in a hospital.

Announces the new Base PowerCharger™ 4 x 4, the first system in the industry to offer a practical solution for improving the reliability, effectiveness, and cost of battery management.

LifeVestを製造する医療機器会社、Lifecore, Incへの出資を行う。

Launches RescueNet®, the only complete EMS information management system that helps improve patient care, operational efficiency, and agency compliance.

Unveils a tablet computer-based 12-lead system to help identify the onset of cardiac arrest.

救急機関向け情報管理システムRescueNetサービス開始

Introduces the M Series® monitor/defibrillator, the most advanced defibrillator worldwide. The product is approximately one-third the size and half the weight of any competitive full-featured defibrillator.

Establishes subsidiaries in Canada and Germany.

Debuts the Rectilinear Biphasic™ defibrillation waveform and is given FDA clearance to label this technology as clinically superior to monophasic defibrillators for the conversion of ventricular fibrillation in high-impedance patients and for cardioversion of atrial fibrillation.

Acquires Pinpoint Technologies to provide a complete information management solution to the EMS market.

Introduces Smart Batteries, an industry first providing users with an accurate run time display.

ZOLLはオーストラリアとフランスに子会社を設立します。

Launches the M Series CCT for critical care transport.

The ZOLL AED Plus® defibrillator is designed in cooperation with hundreds of first responders and EMS agencies.

Receives 510(k) marketing clearance from the FDA for its AED Plus defibrillator and the new CPR-D-padz® electrodes, the first system to provide instantaneous feedback on the depth and rate of chest compressions during CPR.

ZOLL provides an initial grant to help establish the AED Instructor Foundation.

ゾルとリコア株式会社は、リコアのライフベストウェアラブル除細動器を米国とカナダの病院に患者用として販売する契約を発表しました。

The M Series CCT is selected as the defibrillator of choice for the U.S. Military Patient Movement Item Program. The agreement, worth $8.9 million, is the single largest order in ZOLL's history.

CPRフィードバック機能付きAEDを開発

Establishes a subsidiary in Austria.

Renames its Pinpoint Technologies subsidiary ZOLL Data Systems to better reflect the EMS market.

Acquires Infusion Dynamics, Inc., which manufactures a unique fluid resuscitation product called the Power Infuser®.

Pediatric capability for the AED Plus receives clearance from the FDA.

Launches CodeNet®, the first complete data management system that solves the problem of hard-to-manage code event data for hospitals.

Introduces the ZOLL AED Pro® for professional rescuers.

Launches the E Series® monitor/defibrillator, designed to meet the specific demands and extreme conditions of the EMS environment.

Completes the acquisition of the assets of LIFECOR, Inc.

Launches the R Series® monitor/defibrillator, the first and only Code-Ready® defibrillator for hospitals.

着用型自動除細動器「LifeVest」の設計・製造・販売を行うLifecor, Inc.の買収を完了

Receives market clearance for E Series with Real CPR Help® technology.

Purchases the temperature management assets of Radiant Corporation.

Surpasses $300 million in revenues.

Receives clearance to market E Series and AED Pro with See-Thru CPR® technology whose functionality helps minimize interruptions in CPR.

STEMI solutions offer enhanced transmission technology for 12-lead ECG.

AED Pro is approved for use on MEDEVAC helicopters, receiving certification that it meets the US Defense Department’s criteria for medical devices after extensive testing by the US Army’s Aeromedical Research Laboratory.

AutoPulse approved for use in China.

LifeVest wearable defibrillator exceeds 10,000 prescriptions.

ZOLL and Welch Allyn enter strategic alliance; ZOLL becomes exclusive distributor of Propaq® LT.

Reaches $398 million in revenues, an increase of 29% over the previous year.

Purchases intravascular temperature management (IVTM™) assets from Alsius Corporation.

New R Series BLS and R Series Plus monitor/defibrillators receive FDA clearance.

Forbes誌「最も信頼できる企業Top 100」に3年連続選出(10社のみ)

Alsius Corporationより、血管内体温管理(IVTM™)事業を買収

Propaq MD monitor/defibrillator and Propaq M monitor granted clearance by the FDA.

LifeVest wearable defibrillator physician prescriptions top 30,000.

AutoPulse Circulation Improving Resuscitation Care (CIRC) trial concludes successfully; first large-scale resuscitation trial to reach a statistically significant result.

Receives Frost & Sullivan 2010 Market Leadership Award for demonstrated excellence in capturing the highest market share of the North American external defibrillator market.

PocketCPR® for iPhone – a training app – is the first to support new 2010 AHA/ERC/ILCOR Guidelines.

Reports record Q4 and annual revenues; breaks the $500 million mark with fiscal 2011 revenues of $523.7 million.

ZOLL PocketCPR

Asahi Kasei acquires ZOLL for $2.21 billion.

Introduces the first pediatric electrodes that report CPR quality on children up to eight years old.

Establishes new Japanese subsidiary Asahi Kasei ZOLL Medical (AZM).

X Series® monitor/defibrillator receives 510(k) clearance from the FDA.

旭化成株式会社がZOLL Medicalを買収

日本国内での販売子会社旭化成ゾールメディカルを設立

First medical device company to sign pledge to make real-time patient information available to clinicians, such as from EMS services to hospitals, in order to reduce preventable deaths.

Introduces the Fully Automatic AED Plus with Real CPR Help, automatically delivering a shock when it detects a shockable heart rhythm.

Expands product portfolio to include ventilation with the acquisition of assets of Impact Instrumentation, Inc.

Acquires Philips InnerCool® temperature management business.

Impact Instrumentation, Incを買収し、人工呼吸器を含め製品ポートフォリオを拡大

Philips社から体温管理システムInnerCool 事業を買収

Acquires Advanced Circulatory Systems, Inc., of Roseville, Minn., developer of the ResQPOD.

ResQCPR® system receives premarket approval from the FDA as it is shown to profoundly increase blood flow to the heart and other vital organs in pre-clinical studies.

ResQPODを開発したAdvanced Circulatory Systems, Incを買収

Receives market approval for intravascular temperature management technology to treat sudden cardiac arrest in Japan.

ZOLL AED 3® and the ZOLL AED 3 BLS automated external defibrillators are approved for marketing and distribution in Europe.

Establishment of the ZOLL EMT Scholarship, awarded to eleven caregivers in the program's inaugural year.

Health Canada approves the ZOLL AED 3 and the ZOLL AED 3 BLS automated external defibrillators for marketing and distribution in Canada.

ZOLL Hospital Wearable Defibrillator (HWD) receives premarket approval from the FDA.

Propaq M selected by U.S. Air Force and U.S. Army as their deployable vital signs monitor.

ZOLL is the first company to receive premarket approval from the FDA on its full portfolio of defibrillators.

VEST trial shows LifeVest wearable defibrillator reduces total mortality by 36% at 90 days.

Heroes for Life program launched to honor sudden cardiac arrest survivors and the "unexpected heroes" who helped save them with a ZOLL AED.

Respond™ app introduced to improve communication and navigation among EMS dispatchers, crews, and clinical staff.

Z Vent® transport ventilator introduced for pre- and intra-hospital use.

FDA approves X Series® Advanced, a monitor/defibrillator that includes Real BVM Help®, technology that provides real-time feedback on delivered ventilation rate and tidal volume. It also features TBI Dashboard™, an interface for monitoring vital signs essential to managing traumatic brain injury.

Acquires Payor Logic, Inc., a company that specializes in best-in-class accounts receivable (A/R) software solutions for the healthcare industry.

Acquires Golden Hour Data Systems, Inc. Accelerates patient charting and revenue cycle management to the EMS market.

ZOLL completes acquisition of Cardiac Science.

Acquires Mobilize Rescue Systems™, which offers interactive trauma systems to help bystanders save lives during medical emergencies.

Introduces µCor™ (pronounced "Micro Core") Heart Failure and Arrhythmia Management System (HFAMS), new technology to improve the management of acute heart failure patients.

Rebrands Payor Logic solution as ZOLL AR Boost™ to better reflect the potential impact of this technology on a wider segment of the healthcare market.

Acquires TherOx®, Inc., which offers SuperSaturated Oxygen (SSO 2) Therapy, a new FDA-approved treatment to help the most severe heart attack patients.

超過飽和酸素療法を提供するTherOx, Incを買収

緊急時の救助者による救命活動をサポートする双方向性の外傷システムMobilize Rescue Systems™を取得

Cardiac Science社の買収を完了

FDA approves next-generation TherOx system for left anterior descending ST-elevation myocardial infarction (LAD STEMI) heart attack patients.

Acquires Respicardia, Inc., a provider of novel implantable neurostimulators for the treatment of moderate to severe Central Sleep Apnea (CSA).

FDA approves next-generation rem edē® EL-X System to treat moderate to severe CSA.

Acquires Itamar Medical, a device and digital health company that provides at-home testing for sleep apnea.

ZOLL launches the Arrhythmia Management System for more informed treatment plans adding biometric data to traditional mobile cardiac telemetry information.

LifeVest has been worn by more than 1 million patients.

ZOLL significantly expands its respiratory care offerings with the acquisition of bellavista®, fabian®, LTV®, and 3100 FHO ventilator product lines from Vyaire Medical.

ZOLL launches Zenix®, an easy-to-use, highly customizable monitor/defibrillator that features groundbreaking clinical advances.